PRT3789 

PRT3789 is a potent, selective and VHL-based SMARCA2 PROTAC degrader. PRT3789 is more selective for SMARCA2 than SMARCA4. PRT3789 has robust inhibition of cell proliferation of SMARCA4-deleted non-small cell lung cancer (NSCLC) cells in vitro and in vivo, but not SMARCA4 wild type cancer cells (Pink: Target protein ligand (HY-44824); Black: linker (HY-79552); Blue: E3 ligase ligand (HY-168143))^[1][2]. (粉色：靶蛋白配体 (HY-44824)；黑色：连接子 (HY-79552)；蓝色：E3 连接酶配体 (HY-112078))

891.09

C₄₇H₅₈N₁₀O₆S

2755761-76-1

CC1=C(SC=N1)C2=CC=C(C=C2)[C@@H](NC([C@@H]3C[C@H](CN3C([C@H](C(C)C)C4=CC(O[C@H](CN5CCC(C5)N6CCN7C8=C(NC[C@H]7C6)N=NC(C9=C(C=CC=C9)O)=C8)C)=NO4)=O)O)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michael Hulse, et al. Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader. June 2022Cancer Research 82(12_Supplement):3263-3263.

  [2]. Discovery of PRT3789, a first-in-human, highly potent and selective SMARCA2 targeted protein degrader.